Trial of the Micronized DHACM Injectable Product Compared to Saline Placebo Injection for the Treatment of Knee OA
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Key objective is to determine the safety and efficacy of the 40 mg and 100 mg doses of
allogeneic micronized dehydrated human amnion/chorion membrane (micronized DHACM) injectable
compared to 0.9% sodium chloride injection, placebo control for the treatment of knee
osteoarthritis